(BAX) Baxter International - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0718131099

IV Solutions, Infusion Devices, Generic Injectables, Surgical Sealants, Dialysis

Stock: Health Care Equipment
Age 44.2y

MCap 10,338m
Avg Vol 8.12M (159M USD)

Beta 0.893
Volatility 35.81%

EPS (Earnings per Share)

EPS CAGR: -51.42%
EPS Trend: -68.6%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: -5.56%
Rev. Trend: -73.0%

Last SUE: -0.03
Qual. Beats: 0

Dividends

Dividend Yield	1.79%
Yield on Cost 5y	0.73%
Yield CAGR 5y	-16.89%
Payout Consistency	37.3%
Payout Ratio	21.6%

Risk via 5d forecast
Volatility	35.8%
Value at Risk 5%th	47.9%
Relative Tail Risk	-18.70%

Reward TTM
Sharpe Ratio	-0.82
Alpha	-48.78
CAGR/Max DD	-0.35

Character TTM
Hurst Exponent	0.584
Beta	0.893
Beta Downside	1.076

Drawdowns 3y
Max DD	62.44%
Mean DD	27.41%
Median DD	25.77%

Description: BAX Baxter International January 03, 2026

Baxter International Inc. (NYSE:BAX) is a U.S.-based, diversified healthcare company that markets a broad range of products-including sterile IV solutions, infusion devices, parenteral nutrition, generic injectables, surgical hemostats, advanced operating-room equipment, smart-bed systems, patient-monitoring tools, and respiratory devices-across hospitals, dialysis centers, ambulatory surgery facilities, and home-care settings.

The firm operates through three segments: Medical Products and Therapies; Healthcare Systems and Technologies; and Pharmaceuticals. Its distribution model blends a direct sales force with independent distributors, drug wholesalers, and specialty pharmacies, and it maintains a global footprint spanning North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Key recent metrics: FY 2023 revenue reached approximately $12.5 billion, with the Medical Products and Therapies segment contributing roughly 65% of sales; operating margin hovered near 12%, reflecting steady cost-control despite inflationary pressure on raw materials. The aging U.S. population and rising chronic-disease prevalence continue to drive demand for Baxter’s infusion and renal-care solutions, while reimbursement reforms in Europe pose a modest upside-risk to margins.

For a deeper quantitative view, you might explore ValueRay’s interactive dashboard on Baxter’s valuation metrics.

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-341.0m TTM) > 0 and > 6% of Revenue (6% = 661.4m TTM)

FCFTA 0.01 (>2.0%) and ΔFCFTA -0.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 28.65% (prev 22.64%; Δ 6.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 749.0m > Net Income -341.0m (YES >=105%, WARN >=100%)

Net Debt (7.99b) to EBITDA (1.03b) ratio: 7.78 <= 3.0 (WARN <= 3.5)

Current Ratio 1.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (514.0m) change vs 12m ago 0.39% (target <= -2.0% for YES)

Gross Margin 35.39% (prev 38.21%; Δ -2.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 46.18% (prev 44.11%; Δ 2.06pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.13 (EBITDA TTM 1.03b / Interest Expense TTM 311.0m) >= 6 (WARN >= 3)

Altman Z'' 4.18

(A) 0.15 = (Total Current Assets 6.93b - Total Current Liabilities 3.77b) / Total Assets 21.07b

(B) 0.70 = Retained Earnings (Balance) 14.84b / Total Assets 21.07b

(D) 0.85 = Book Value of Equity 11.79b / Total Liabilities 13.85b

Total Rating: 4.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.13

1. Piotroski 2.50pt

2. FCF Yield 1.26%

3. FCF Margin 2.09%

4. Debt/Equity 1.34

5. Debt/Ebitda 7.78

6. ROIC - WACC (= -4.79)%

7. RoE -4.77%

8. Rev. Trend -72.98%

9. EPS Trend -68.58%

What is the price of BAX shares?

As of January 20, 2026, the stock is trading at USD 20.11 with a total of 7,593,078 shares traded.
Over the past week, the price has changed by -0.20%, over one month by +5.45%, over three months by -13.01% and over the past year by -34.96%.

Is BAX a buy, sell or hold?

Baxter International has received a consensus analysts rating of 3.44. Therefor, it is recommend to hold BAX.

Strong Buy: 4
Buy: 2
Hold: 11
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the BAX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	23.1	15%
Analysts Target Price	23.1	15%
ValueRay Target Price	16	-20.7%

BAX Fundamental Data Overview January 19, 2026

P/E Forward = 8.569
P/S = 0.9378
P/B = 1.4277
P/EG = 37.2697
Revenue TTM = 11.02b USD
EBIT TTM = 41.0m USD
EBITDA TTM = 1.03b USD
Long Term Debt = 8.75b USD (from longTermDebt, last quarter)
Short Term Debt = 755.0m USD (from shortTermDebt, last quarter)
Debt = 9.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.99b USD (from netDebt column, last quarter)
Enterprise Value = 18.32b USD (10.34b + Debt 9.71b - CCE 1.73b)
Interest Coverage Ratio = 0.13 (Ebit TTM 41.0m / Interest Expense TTM 311.0m)
EV/FCF = 79.67x (Enterprise Value 18.32b / FCF TTM 230.0m)
FCF Yield = 1.26% (FCF TTM 230.0m / Enterprise Value 18.32b)
FCF Margin = 2.09% (FCF TTM 230.0m / Revenue TTM 11.02b)
Net Margin = -3.09% (Net Income TTM -341.0m / Revenue TTM 11.02b)
Gross Margin = 35.39% ((Revenue TTM 11.02b - Cost of Revenue TTM 7.12b) / Revenue TTM)
Gross Margin QoQ = 33.51% (prev 40.25%)
Tobins Q-Ratio = 0.87 (Enterprise Value 18.32b / Total Assets 21.07b)
Interest Expense / Debt = 0.60% (Interest Expense 58.0m / Debt 9.71b)
Taxrate = 21.0% (US default 21%)
NOPAT = 32.4m (EBIT 41.0m * (1 - 21.00%))
Current Ratio = 1.84 (Total Current Assets 6.93b / Total Current Liabilities 3.77b)
Debt / Equity = 1.34 (Debt 9.71b / totalStockholderEquity, last quarter 7.24b)
Debt / EBITDA = 7.78 (Net Debt 7.99b / EBITDA 1.03b)
Debt / FCF = 34.72 (Net Debt 7.99b / FCF TTM 230.0m)
Total Stockholder Equity = 7.15b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.43% (Net Income -341.0m / Total Assets 21.07b)
RoE = -4.77% (Net Income TTM -341.0m / Total Stockholder Equity 7.15b)
RoCE = 0.26% (EBIT 41.0m / Capital Employed (Equity 7.15b + L.T.Debt 8.75b))
RoIC = 0.18% (NOPAT 32.4m / Invested Capital 17.70b)
WACC = 4.97% (E(10.34b)/V(20.05b) * Re(9.20%) + D(9.71b)/V(20.05b) * Rd(0.60%) * (1-Tc(0.21)))
Discount Rate = 9.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.69%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈357.6m ; Y1≈234.7m ; Y5≈107.1m
Fair Price DCF = N/A (negative equity: EV 3.41b - Net Debt 7.99b = -4.57b; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: -68.58 | EPS CAGR: -51.42% | SUE: -4.0 | # QB: 0
Revenue Correlation: -72.98 | Revenue CAGR: -5.56% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.49 | Chg30d=-0.013 | Revisions Net=+0 | Analysts=9
EPS next Year (2026-12-31): EPS=2.27 | Chg30d=-0.036 | Revisions Net=-2 | Growth EPS=-4.1% | Growth Revenue=+2.3%

Additional Sources for BAX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle